Current Updates in Gene Therapy for Multiple Sclerosis

Simple item page
dc.contributor.authorHossam Tharwat Ali
dc.contributor.authorHaya Mohamed
dc.contributor.authorYara Ashour
dc.contributor.authorIdris Sula
dc.contributor.authorAhmed Elrefaey
dc.contributor.authorMennatullah Mohamed Eltaras
dc.contributor.authorMostafa Meshref
dc.date.accessioned2023-09-06T10:36:35Z
dc.date.available2023-09-06T10:36:35Z
dc.date.issued2023-05-16
dc.description.abstractBackground: Multiple sclerosis (MS) is the most common demyelinating disease affecting predominantly young adults. The underlying pathogenesis isn’t fully understood although autoimmune attacks against proteins in the CNS is the most accepted theory. Oligodendrocytes seem to be the most involved resulting in demyelinated axons. Currently, the management of MS focuses on relieving symptoms during acute attacks and preventing disease progression using disease-odifying agents such as interferon-beta, dimethyl fumarate, natalizumab, and fingolimod. Studies have proven long-term improvement on these drugs. However, possible side effects and curatively inducing or improving the repair process are major challenges.
dc.description.sponsorshipAl-Quds University
dc.identifier.urihttps://dspace.alquds.edu/handle/20.500.12213/8600
dc.language.isoen
dc.publisherAl-Quds University - Deanship of Scientific Research
dc.titleCurrent Updates in Gene Therapy for Multiple Sclerosis
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Current Updates in Gene Therapy for Multiple Sclerosis.pdf
Size:
243.47 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.61 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medicine & Public Health